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Abstract
The switching defective/sucrose non-fermenting (SWI/SNF) complexes play an important role in hepatic lipid metabolism
regulating both transcriptional activation and repression. BAF60a is a core subunit of the SWI/SNF chromatin-remodeling
complexes that activates the transcription of fatty acid oxidation genes during fasting/glucagon. BAF60c, another subunit
of SWI/SNF complexes, is recruited to form the lipoBAF complex that activates lipogenic genes, promoting lipogenesis
and increasing the triglyceride level in response to feeding/insulin. Interestingly, hepatocytes located in the periportal and
perivenous zones of the liver display a remarkable heterogeneity in the activity of various enzymes, metabolic functions
and gene expression. Especially, fatty-acid oxidation was shown to be mostly periportal, whereas lipogenesis was mostly
perivenous. Therefore, the present review highlights the role of of SWI/SNF regulating lipid metabolism under nutritional
and hormonal control, which may be associated with hepatocyte heterogeneity.
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Background
Understanding the regulation of hepatic lipid metabolism is
critical as this metabolic disorder is often linked to chronic
pathological conditions such as fatty liver, obesity, diabetes
and cardiovascular disease [1, 2]. Ectopic accumulation of
lipid in the liver is an early pathogenic event in the develop-
ment of nonalcoholic steatohepatitis, characterized by
chronic inflammation and liver damage [3, 4]. In recent
years, liver lipid metabolism disorders leading to metabolic
syndrome are receiving considerable attention. It is well
known that lipid metabolism is influenced by several regu-
latory factors. In this regard, recent studies have shown that
the relationship between the upstream stimulatory factor
(USF) and the sterol regulatory element-binding protein 1c
(SREBP-1c), are two transcription factors shown to be
crucial for regulation of lipogenesis [5, 6]. Furthermore, the
peroxisome proliferator-activated receptor γ co-activator
protein-1α (PGC-1α) was found to play an important role
in the regulation of fatty acid β-oxidation (FAO) by inter-
acting with the peroxisome proliferatoractivated receptor-α
(PPARα) [7–9].
Other studies have shown a remarkable heterogeneity of
periportal- and perivenous hepatocytes along the porto-
central axis with respect to ultrastructure and enzyme
activities resulting in different cellular functions within
different zones of the liver lobule [10, 11]. However, the
mechanism underlying zonation was poorly understood in
spite of a number of hypotheses that have been proposed.
Interestingly, lipid metabolism, with fatty acid oxidation
preferentially occurs in the periportal area, whereas lipo-
genesis takes place predominantly in the perivenous zone
[11, 12]. The perivenous hepatocytes have a higher cap-
acity for the de novo synthesis of fatty acids; in which the
activities of lipid metabolism such as ATP citrate lyase
(ACL) [13], acetyl-CoA carboxylase (ACC) [14], and fatty
acid synthase (FAS) [15, 16] are higher than that in peri-
portal hepatocytes.
The SWI/SNF chromatin-remodeling complex is known
to be involved in the regulation of lipid metabolism
[17, 18]. BAF60a and BAF60c, two subunits of the
SWI/SNF chromatin-remodeling complexes, are import-
ant for maintaining hepatic lipid metabolism. Studies have
identified BAF60a and PPARα interacts with PGC-1α for
the formation of a transcriptional complex to transcrip-
tional activation of fatty acid oxidation genes during
fasting [17]. In contrast, BAF60c recruitment through
USF-1 in response to feeding/insulin is specific to
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lipogenic genes [18]. In this review, we have discussed that
under the control of nutritional and hormonal signals, the
regulation of hepatic lipid metabolism by SWI/SNF may
be involved in the heterogeneity of hepatocytes.
BAF60a/BAF60c their effects on chromatin-
remodeling
SWI/SNF chromatin-remodeling complexes
The components of the switching defective/sucrose non-
fermenting (SWI/SNF) chromatin-remodeling complex
were initially identified in screens for genes that regulate
mating-type switching and sucrose non-fermenting phe-
notypes in yeasts [19–21]. The SWI/SNF complex com-
ponents (Fig. 1) contain one of two catalytic ATPases
subunits, BRM (brahma, also known as SMARCA2) and
BRG1 (brahma-related gene 1, also known as SMARCA4).
Each ATPase has 10 to 12 proteins known as BAFs (BRG1-
or BRM-associated factors) consisting of core and accessory
subunits. The SWI/SNF core subunits include BAF155,
BAF170, and SNF5 (also referred to as SMARCB1, BAF47,
or INI1). The structure of this multiprotein complex was
constructed by superimposing the predicted binary interac-
tions between BAF155 and BRG1, BRG1 and SNF5, and
SNF5 and BAF170 [22]. BAF155 maintains a scaffolding-
like function, and can influence both stability and assembly
of other SWI/SNF subunits [23]. SNF5 has a mediating
function in recruiting transcription factors to the SWI/SNF
complex. The function of BAF170, which shares homology
with BAF155 is less well understood, but it may also
control the levels of other SWI/SNF subunits. Thus,
the core SWI/SNF subunits encompass widely distinct
biochemical and functional activities. The accessory
subunits BAF60 proteins have been shown to interact
with transcription factors, including nuclear receptors,
the AP-1 complex, and others, and are thought to
bridge interactions between these transcription factors
and BAF complexes [24]. The BAF60 family includes:
BAF60a, BAF60b, and BAF60c. They show different
expression patterns among tissues and interact with
different combinations of nuclear receptors as mediators
[25]. The SWI/SNF family of chromatin-remodeling
complexes are master regulators of transcription factor
action and resultant gene expression programs [26–28].
The SWI/SNF complex is an ATP-dependent chromatin-
remodeling complex, which uses the energy of ATP
hydrolysis to alter the location or conformation of nucleo-
somes [29]. Other nonredundant chromatin remodeling
complexes endowed with ATPase activity include the ISWI
(imitation SWI), CHD (chromodomain and helicase-like
domain), and INO80 (inositol requiring 80) families of
remodelers [30]. The SWI/SNF complexes have been found
to be implicated in the regulation of diverse biological pro-
cesses, including embryogenesis, cell cycle, differentiation,
and tumorigenesis [31, 32]. The SWI/SNF chromatin-
remodeling complexes utilize either BRG1 or BRM as
alternative catalytic subunits to regulate gene expression
[33]. The BRG1 protein can be found assembled with
transcription factors and histone-modifying enzyme com-
plexes to activate or repress nuclear processes including
transcription, elongation and DNA replication [34]. The
combinatorial association of SWI/SNF subunits appears to
generate a functional diversity that might be critical for
controlling finely selective and cell type-specific develop-
mental and regeneration decisions [35]. The perturbation of
SWI/SNF chromatin remodeling complexes is an emerging
theme in cancer initiation and progression [36]. Several
reports have shown mutations and/or loss of BRG1 in hu-
man cancer cell lines and primary tumors [37, 38]. Support-
ing a role in cancer initiation, loss of heterozygosity of the
region surrounding BRG occurs with significant frequency
in human adenocarcinomas. Studies have also found that
the SWI/SNF complexes regulate cardiovascular develop-
ment and lipid homeostasis [39, 40]. Overall, the compos-
ition of SWI/SNF complexes, which varies by cell type,
differentiation stage, and metabolism, might alter the func-
tional interactions with other chromatin modifiers and tran-
scription factors, dictating the specificity for target genes.
BAF60a function in chromatin-remodeling
In mammals, the BAF complex is a multi-subunit com-
plex that alters the nucleosomes, and is often considered
the last step required for transcriptional activation.
Within BAF complexes, there are BAF60s proteins that
Fig. 1 Components of the SWI/SNF complex. SWI/SNF complexes consist of a single ATPase (BRM or BRG1) core subunits (BAF155, BAF170, and
SNF5) and accessory subunits (BAF60a, b, or c; BAF57; BAF53)
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are thought to form a recruitment bridge between DNA-
binding transcription factors and other BAF subunits
[17]. BAF60a was initially identified as a determinant of
the transactivation potential of Fos/Jun dimers to induce
the endogenous AP-1-regulated genes such as collage-
nase and c-met [41]. BAF60a is a subunit of the BAF60
family, regulating nucleosome and chromatin structures
through ATP hydrolysis [25]. BAF60a mRNA is present
in several tissues, including brain, skeletal muscle, and
liver. BAF60a, through Nand C-terminal domains, inter-
laces BRG1 with BAF170 and BAF155, which forms the
core-remodeling complex. It is recruited to the promoter
region of a target gene by the specific transcription fac-
tor and remodels nearby nucleosomes to facilitate or re-
press transcription [42]. Studies have also demonstrated
[41, 43] that BAF60a recruit SWI/SNF complexes to
regulate metabolic gene programs in the liver and skel-
etal muscle. BAF60a has been linked to lung cancer risk,
binds to p53 and is necessary for steroid receptor func-
tion [44]. This suggests a pleiotropic role of BAF60a in
cellular and organismal biology by integrating endocrine,
metabolic, and circadian signals [45]. BAF60 associates
with BRG1/BAF190, potentially functioning as a bridge
between DNA-binding transcription factors and other
BAF subunits [44, 46].
The BAF60a is a tissue-specific role of the BAF60 iso-
forms, perhaps by association with distinct regulators. It is
involved in the regulation of a specific metabolic gene net-
work in the liver. Gatfield demonstrated that miR-122,
which is a highly abundant, hepatocyte-specific micro-
RNA, controls the circadian expression of BAF60a and
mediates the regulation of cholesterol and lipid metabol-
ism through a crosstalk with BAF60a and PPAR β/δ [47].
BAF60a is a diet-sensitive factor that controls a hepatic
gene program responsible for bile acid synthesis and
intestinal cholesterol absorption through a BAF60a/
constitutive androstane receptor (CAR) of the feed-
forward regulatory loop in the liver [48]. BAF60a activates
a CAR-dependent program of gene expression in the liver
to regulate bile acid and cholesterol metabolism. Disrup-
tion of this pathway by liver-specific inactivation of
BAF60a protects mice from diet-induced hypercholester-
olemia and atherosclerosis. The positive effects of BAF60a
on glucose levels may due to the induction of gluconeo-
genic genes such as glucose-6-phosphatase (G6Pase) and
phosphoenolpyruvate carboxykinase (PEPCK) and the ac-
celerated rate of gluconeogenic process [46]. BAF60a may
be also involved in fatty acid β-oxidation by interacting
with PGC-1α [17]. Fatty acid β-oxidation is an important
component of hepatic lipid homeostasis.
BAF60c function in chromatin-remodeling
BAF60c, a component of the SWI/SNF chromatin-
remodeling complex, is one of the first SWI/SNF subunits
described to directly interact with transcriptional activa-
tors [49]. It is localized primarily in the cell nucleus and is
expressed in a wide variety of tissues. BAF60c has been
proposed to serve as a bridge between transcription fac-
tors and the ATPase-dependent chromatin remodeling
BAF complex. BAF60c may play a role in heart develop-
ment. BAF60c overexpressed in cell culture can mediate
interactions between cardiac transcription factors and the
BAF complex ATPase BRG1, thereby potentiating the acti-
vation of target genes [24, 50]. Silencing of BAF60c gene
using siRNA in mouse embryos causes defects in heart
morphogenesis as well as abnormal cardiac and skeletal
muscle differentiation [24]. Studies found that BAF60c
can regulate gene expression in muscle by interacting with
MyoD [51, 52]. Recently, Baf60c has been identified that
interacts with selective transcription factors, as a core
component of a regulatory cascade that drives glycolytic
myofiber formation [44]. It promotes a shift from oxida-
tive to glycolytic metabolism in the muscle through its in-
duction of Deptor expression and Akt activation [43, 44].
The oxidative-to-glycolytic metabolic shift was accompan-
ied by higher glycolytic and lower oxidative gene expres-
sion. In addition, BAF60c is required for maintaining
glycolytic capacity in adult skeletal muscle in vivo. BAF60c
interacts with peroxisome proliferator-activated receptor γ
(PPARγ) in a ligand-independent manner to enhance its
transcriptional activity. The PPARγ is one of the three
PPARs that together constitute a distinct subfamily of nu-
clear receptors. It has mostly been studied because of its
key role in adipocyte differentiation, but it has many add-
itional functions [16]. Nevertheless, Debril [49] reported
that BAF60c does not seem to affect adipocyte differenti-
ation and cell proliferation. On the other hand, BAF60c is
specific for chromatin remodeling and transcription of
lipogenic genes in response to insulin. BAF60c is reported
to promote lipogenesis in vivo and that it increases trigly-
ceride levels, demonstrating its role in metabolic adaption
to activate the lipogenic program in response to feeding
and insulin [18]. BAF60c is a subunit of functional diver-
sity and may be related to the regulation of diseases.
Hepatocyte heterogeneity and lipid metabolism
Metabolic zonal functions in liver
The liver plays a most important metabolic role through-
out the body, receiving its supply of hydrophilic nutrients
absorbed by the intestine via the portal vein and delivering
metabolized products to the other organs via the central
vein [53]. Since the pioneering work of Jungermann on
this subject, this functional heterogeneity is referred to as
“metabolic zonation” of the liver, and demonstrated that
the hepatocytes heterogeneity along the porto-central axis
with respect to ultrastructure and enzyme activities result-
ing in different cellular functions within different zones of
the liver lobuli [10, 54, 55]. Based on the location of the
Zhang et al. Nutrition & Metabolism  (2016) 13:30 Page 3 of 13
blood vessels, the terminal branches of the portal and the
hepatic (central) veins and on the direction of the blood
flow, hepatocytes of each liver lobule can be divided into
two subpopulations, an upstream ‘periportal’ and a down-
stream ‘perivenous’ population [11]. Hepatocytes located
in both zones of the liver lobuli show remarkable differ-
ences in the levels and activities of various enzymes and
subcellular structures and thus have different metabolic
capacities. The results obtained in several studies are sum-
marized in Table 1. It is observed that gluconeogenesis,
aminoacid degradation, ureagenesis, fatty-acid oxidation,
and cholesterol synthesis are mostly located in the peri-
portal hepatocytes whereas glycolysis, ketogenesis, glu-
tamine synthesis, lipogenesis, and xenobiotic metabolism
are preferentially situated in the perivenous hepatocytes
[55, 62–65]. Therefore, the model of metabolic zonation
proposes a functional specialization for the two zones of
the liver.
Periportal hepatocytes and fatty acid oxidation
Fatty acids are oxidized in three cellular organelles of
liver cells, with β-oxidation confined to mitochondria
and peroxisomes, with CYP4A catalyzed ω-oxidation
taking place in the endoplasmic reticulum [66, 67]. The
major pathway for the catabolism of fatty acids is mito-
chondrial fatty acid β-oxidation [66, 68]. This oxidation
is a complex process taking place the in liver and
involves the participation of several enzymes that are
influenced by multiple factors. Enzymes such as
carnitine palmitoyltransferase 1 (CPT1) and carnitine
palmitoyltransferase 2 (CPT2), and substrates (fatty acid
metabolism intermediates), such as malonyl-CoA are
known to influence mitochondrial fatty acid β-oxidation
[69]. The enzymes involved in the oxidation of fatty
acids are also under a high degree of transcriptional con-
trol, and conditions that upregulate fatty acid β-
oxidation are often associated with increases in the ex-
pression of a number of β-oxidation enzymes [70].
Fatty acid oxidation is a metabolic pathway underlying
zonal expression in liver as two genes, encoding phos-
phatide phosphatase and apolipoprotein C2, a cofactor
for activation of lipoprotein lipase, found in our study to
be preferentially expressed in the periportal hepatocytes
subpopulation [11]. In liver, fatty acids are utilized for
oxidative energy supply, ketogensis and for the synthesis
and release of triglycerides as very low-density lipopro-
teins. Moreover, only the liver can convert fatty acids to
ketone bodies, which are important alternative energy
substrates for many tissues, including the brain. Since
the oxidative capacity is higher in periportal hepatocytes,
it was postulated that the fatty acid oxidation via β-
oxidation should also be localized in this zone [55].
Perivenous hepatocytes and lipogenesis
Lipogenesis encompasses fatty acid synthesis and their
utilization for phospholipid and triglyceride generation.
By catalyzing seven reactions in fatty acid synthesis
acetyl-CoA is converted to malonyl-CoA, the rate-
Table 1 Predominant localization of the major metabolic functions and proteins in zones of hepatocytes
Periportal zone Perivenous zone References










Gluconeogenesis G6Pas, FBPas, PEPCK, Lactate
dehydrogenase
Glycolysis GK, PKL [10, 11, 55, 58],
Glycogen synthesis
Alanine aminotransferase
Ammonia and aminoacid utilization
Urea synthesis, Aminoacid
degradation
CPS1, OTC, ASS, Arg, TAT, SerDH, Alanine
aminotransferase










Abbreviations: CPI carnitine palmitoyltransferase I, ACC acetyl-CoA carboxylase, ACL ATP citrate lyase, FAS fatty acid synthase, G6Pas glucose-6-phosphatase, FBPas
fructose-1,6-bisphosphatase, PEPCK phosphoenolpyruvate carboxykinase, GK glucokinase, PKL pyruvate kinase isoenzyme L, CPS1 carbamoylphosphate synthetase,
OTC ornithine carbamoyl transferas, ASS arginine succinate synthetase, Arg1 Arginase 1, TAT tyrosine aminotransferase, SerDH serine dehydratase, GS glutamine
synthase, GST glutathione S-transferase
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limiting step in the lipogenesis pathway, catalyzed mainly
by ACC [71]; Successive molecules of malonyl-CoA,
which serves as a two carbon donor, are added to the
acetyl-CoA primer by a multifunctional enzyme complex,
the fatty acid synthase [72]. Fatty acid synthase plays a
central role in de novo lipogenesis [73]; palmitic acid
(C16:0) is the predominant fatty acid generated by fatty
acid synthase [74]. Palmitic acid is desaturated by
stearoyl-CoA desaturase-1(SCD-1) to palmitoleic acid or
elongated to yield stearic acid (C18:0). Furthermore, stud-
ies have reported that the rate of lipogenesis and the activ-
ity of ACL, ACC, and FAS are considerably higher in the
periportal than in the perivenous zone of the liver [12, 75].
In addition, fatty acid and fat synthesis in the liver is a
highly regulated metabolic pathway that is important for
very low-density lipoprotein (VLDL) production and thus
energy distribution to other tissues. Docosahexaenoic and
eicosapentaenoic acids reduced the secretion of chylo-
micron and VLDL partly by regulating the synthesis of tri-
acylglycerol and apolipoprotein B [76]. Having common
features at their promoter regions, lipogenic genes are co-
ordinately regulated at the transcriptional level. Tran-
scription factors, such as USFs, SREBP-1c, liver X
receptors (LXRs) and carbohydrate-responsive element-
binding protein (ChREBP) have crucial roles in this
process. SREBPs are the basic helixloophelix leucine
zipper (bHLH-LZ) transcription factors that bind as di-
mers to sterol regulatory elements (SREs) of target
genes involved in lipid metabolism [77]. There are three
SREBP isoforms: SREBP-1a, SREBP-1c, and SREBP-2,
of which SREBP-1c is primarily responsible for the ex-
pression of lipogenic genes, although there is some
functional overlap between different SREBPs. SREBP-1c
is highly expressed in lipogenic tissue. It activates hep-
atic fatty acid synthesis through regulation of lipogenic
genes [78, 79], such as ACL, ACC and FAS [80, 81].
SREBP-1c target genes encode a rate-limiting enzyme
of the fatty acid elongase complex, which converts
palmitate to stearate (C18:0) [80, 82]; the stearoyl-CoA
desaturase-1, which converts stearate to oleate (C18:1);
and glycerol-3-phosphate acyltransferase, the first com-
mitted enzyme in triglyceride and phospholipid synthesis
[80, 83]. In addition to SREBP-1c, the critical role of USF
in lipogenic gene transcription has been demonstrated in
vivo in USF-knockout mice that have significantly im-
paired lipogenic gene induction [84]. Although it is
possible that other SREBP isoforms might compensate for
SREBP-1c, the partial effect of its ablation on hepatic lipo-
genesis is more likely to reflect the contribution of other
transcription factor(s), such as USFs, ChREBP, and LXRs,
which are required for, lipogenic gene induction or its
enhancement. Having common features at their promoter
regions, lipogenic genes are coordinately regulated at the
transcriptional level.
Nutrient supply and the regulation of BAF60a on
hepatic fatty acid oxidation
Regulation of fat oxidation by PGC-1α and PPARα
Fatty acid oxidation occurs in the liver and is strongly
enhanced during fasting as a result of increased fatty
acid influx and altered hormonal signals. The increase of
fat oxidation during fasting is accompanied by transcrip-
tional activation of peroxisomal and mitochondrial fatty
acid β-oxidation genes. The gene program of fat oxida-
tion is regulated by several transcription factors and co-
factors, including PPARα, PGC-1α, and BAF60a [17, 85].
Studies have shown that PPARα plays a key role in he
transcriptional control of encoding genes related to lipid
metabolism in the liver, including those involved in mito-
chondrial β-oxidation, peroxisomal β-oxidation, fatty acid
uptake and/or binding, and lipoprotein assembly and
transport [86–89]. PPARα is a member of the nuclear hor-
mone receptor superfamily. It is primarily expressed in
brown adipose tissue and the liver, and to a lesser extent
in the kidneys, skeletal muscle, and heart [90]. Previous
studies have demonstrated that PPARα transcriptionally
by regulates all key enzymes of peroxisomal and mito-
chondrial β-oxidation pathways [66, 91–96]. PPARα-null
mice were either fasted or fed a high fat diet to investigate
the role of PPARα under these physiological conditions
[97]. Fasted PPARα-null mice show enhanced accumula-
tion of lipid in the liver, suffer from severe hypoglycemia
and hypothermia, and reveal a dramatic inhibition of fatty
acid uptake and oxidation. Furthermore, it is shown that
to accommodate the increased requirement for hepatic
fatty acid oxidation PPARα mRNA is induced in wild-type
mice during fasting. These results indicate that PPARα is
a key transcriptional regulator of fatty acid oxidation genes
and is essential for hepatic fat oxidation during starvation.
In addition, studies have also found that PGC-1α acti-
vates the expression of PPARα target genes involved in
hepatic fatty acid oxidation [98, 99]. PGC-1α physically
interacts with PPARα and increases its transcriptional
activity [100]. One of the roles for PGC-1 as a PPARα
co-activator is to control cellular fatty acid oxidation
[100]. PGC-1 is critical for PPARα interaction and tran-
scriptional activation, two distinct processes. PGC-1α
has been identified as a binding partner and co-activator
of the transcriptional activity of PPARγ as part of a study
to identify transcriptional components of the pathway re-
sponsible for metabolic changes that include glucose and
lipid homeostasis and mitochondrial oxidative metabolism
[101]. It in enriched in metabolic tissues such as muscle,
heart, and liver, where it interacts with multiple DNA-
binding transcription factors. The co-transcriptional activ-
ity of PGC-1α in liver is important for the compensatory
metabolic responses that occur during food deprivation.
Acute RNA interference-mediated PGC-1α knockdown
leads to profound down-regulation of fatty acid oxidation
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gene expression during short-term starvation [98]. Rates
of fatty acid oxidation are also diminished in isolated
hepatocytes from PGC-1α-deficient mice [102]. In this
complex hormonal and nutrient regulation, PGC-1α is
controlled and recruited to regulate gene expression of
hepatic fatty acid oxidation enzymes. Studies shown that
general control non-repressed protein 5 (GCN5) is able to
acetylate PGC-1α and suppress its activity, but evidence
for the dietary control of this process is somewhat limited
[103]. In contrast, PGC-1α is heavily deacetylated by
Sirtuin-1 NAD+-dependent deacetylase (SIRT1) and acti-
vates its activity. SIRT1 is a NAD+-dependent protein dea-
cetylase that has been implicated in several physiological
processes in mammals, including control of lipolytic rates
in white adipose tissue. Moreover, levels of NAD+ have
been shown to change in response to nutrient availability.
For example, the concentration of intracellular NAD+ in-
creased during fasting in the liver of rodents [87, 104,
105]. Consequently, acetyl transferase GCN5 and deacety-
lase SIRT1 are capable of changing the acetylation state of
PGC-1α in response to nutrient state and reciprocally
alter the transcriptional coactivating properties of PGC-1α
[106, 107], providing a new metabolic regulator that
allows mammalian cells to switch from glucose to fatty
acid oxidation in nutrient deprivation conditions [108].
Recently, the hormone fibroblast growth factor (FGF21)
was also shown to be induced in liver during fasting, in-
duces hepatic expression of PGC-1α, and activation of
hepatic lipid oxidation, triglyceride clearance, and keto-
genesis [109–111]. PGC-1α participates in the regulation
of fatty acid oxidation by a complex network of transcrip-
tion factors under the condition of hormonal and nutrient
signals.
Interaction of BAF60a, PGC-1α, and PPARα
BAF60a is a subunit of the SWI/SNF chromatin-
remodeling complexes that activates or represses the tran-
scription of diverse target genes. Studies found that BAF60a
induces the expression of genes involved in peroxisomal
fatty acid β-oxidation in a dosedependent manner, includ-
ing acetyl-Coenzyme A acyltransferase 1B (Acaa1b), acyl-
Coenzyme A oxidase 1 (Acox1), hydroxyacyl-CoA dehydro-
genase (Hadha), and enoyl-Coenzyme A hydratase 1 (Ech1)
[17]. BAF60a also induces the expression of mitochondrial
fatty acid β-oxidation genes, such as acetyl-CoA acyltrans-
ferase 2 (Acaa2), CPT1, and Hadha [17]. Also in that study
in mice liver, the RNAi knockdown RNAi knockdown of
BAF60a were studied and showed that the mRNA levels of
key enzymes in the fatty acid β-oxidation pathway, includ-
ing Acaa1b, Acox1, Acaa2, and Hadha are significantly
lower. These results suggest BAF60a plays an important
role in hepatic fat oxidation.
BAF60a as a transcription factor has been demonstrated
to link the SWI/SNF complexes to the transcriptional
coactivator PGC-1α, suggesting there is a role for BAF60a
in hepatic lipid metabolism. Adenoviral-mediated expres-
sion of BAF60a stimulates the entire program of peroxi-
somal and mitochondrial fat oxidation and lowers liver
triglyceride content in mouse models of hepatic steatosis.
Also, BAF60a is required for the activation of hepatic fat
oxidation during fasting. PGC-1α was found to be essen-
tial for the function of BAF60a as a regulator of fatty acid
oxidation genes to transcriptional activation of peroxi-
somal and mitochondrial lipid oxidation genes in hepato-
cytes. Since both BAF60a and PGC-1α increase mRNA
levels of several fatty acid β-oxidation genes, including
Acaa1b, Acox1, and Hadha simultaneous expression of
these two factors leads to significantly higher induction of
target genes [7].
BAF60a is a recently described circadian regulator that
links time of day to liver metabolic physiology. Tao dem-
onstrated that BAF60a plays a critical role in the coordi-
nated regulation of hepatic circadian clock and energy
metabolism in mammals [46]. Knockdown of BAF60a in
the liver significantly disrupted the rhythmic expression
patterns of clock genes including Bmal1, Per1, Per2,
Rev-erbα, and Cry1, as well as of genes involved in key
metabolic pathways including gluconeogenesis, glucose
oxidation, fatty acid β-oxidation, and mitochondrial res-
piration. Other studies found that BAF60a is also an im-
portant integrator linking the circadian clock and the
physiological homeostasis of vascular smooth muscle cells
(VSMCs) [112]. BAF60a co-activates with the retinoid-
related orphan receptor (ROR) family of orphan nuclear
receptors to stimulate Bmal1 transcription and is essential
for normal circadian rhythms in VSMCs. Notably, during
the development of cardiovascular diseases, such as ath-
erosclerosis, the phenotype of VSMCs will transit from
contractile to synthetic and, correspondingly, there are no-
ticeable cell behavior changes [113]. Similarly, PGC-1α is
a critical component of the mammalian clock. PGC-1α
stimulates the expression of Bmal1 through coactivating
the ROR family of orphan nuclear receptors and is essen-
tial for normal circadian rhythms [114].
Moreover, BAF60a and PPARα have a functional cross-
talk in the regulation of fatty acid oxidation gene tran-
scription [17]. Previous transcriptional profiling studies
have demonstrated that activation of PPARα by WY14643
(an experimental hypolipidemic drug) was found to in-
crease the induction of fatty acid oxidation genes (Acaa1b,
Acox1, and Hadha) by BAF60a providing more evidence
for the existence of a connection between BAF60a and the
PPARα pathway [17, 115]. The transcriptional function of
BAF60a is significantly impaired in PPARα-null hepato-
cytes. Despite this, BAF60a is still capable of activating the
expression of fatty acid oxidation genes in the absence of
PPARα, suggesting that both PPARα-dependent and
PPARα-independent pathways mediate the metabolic
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effects of BAF60a on hepatic fat oxidation [17]. At the
molecular level, BAF60a is required to PPARα-binding
sites on the fatty acid oxidation gene. BAF60a may be re-
cruited for fatty acid oxidation gene promoters through its
direct interaction with PPARα [17]. PPARα plays a pivotal
role in the control of cellular fatty acid utilization path-
ways in response to diverse physiologic conditions includ-
ing fasting [97, 116, 117], nutritional alterations [97], and
aging [118]. The PPARα regulatory pathway has also been
implicated in disease states including cardiac hypertrophy
[119], obesity [120], and diabetes mellitus [116, 120, 121].
The BAF60a/PGC-1α complex is required for the tran-
scriptional function of PPARα in the context of hepatic
lipid metabolism. BAF60a also induces the expression of
PEPCK as well as several clock genes, raising the possibil-
ity that the BAF60a/PGC-1α interaction may play a more
general role in the transcriptional regulation by PGC-1α
[122]. The interaction of BAF60a with PGC-1α and
PPARα, leads to stimulation of specific transcriptional
programs.
Nutrient supplies and the regulation of BAF60c
on hepatic lipogenesis
The physical interaction between BAF60c and USF
USF proteins are members of the basic-helix-loop-helix
(bHLH) family of transcription factors. First identified for
their involvement in transcription from the adenovirus
major late promoter [123, 124], USF proteins were puri-
fied as the 43-kDa USF-1 and 44-kDa USF-2 [121]. USF-1
and USF-2 are homo-or heterodimers that bind to an E-
box with identical DNA binding specificity as target pro-
moters for transcriptional activation [125, 126]. USFs are
found to bind to the proximal promoter region of the gene
encoding fatty acid synthase, which is a key enzyme in
lipogenesis [126]. It has been shown that USFs are re-
quired for FAS promoter activation by insulin by binding
to the -65E-box [127]. The critical role of USF in lipogenic
gene transcription has been demonstrated in vivo using
USF knockout mice that have significantly impaired lipo-
genic gene induction [84]. Together, these results indicate
that phosphorylation-dependent acetylation of USF-1
functions as a sensor for nutritional/insulin status to acti-
vate FAS transcription. Many other lipogenic genes con-
tain closely spaced E-boxes and SREs in their proximal
promoter regions, and therefore may also be subject to
transcriptional regulation by USF-1. USF plays a pivotal role
as a molecular switch by recruiting distinct transcription fac-
tors and coregulators in a fasting/feeding- dependent man-
ner [128].
Since BAF60 is known to function as an anchor point
between transcription factors and the BAF complex,
Wong [5] first found that BAF60c directly interacts with
USF-1 to form lipogenic gene promoters upon feeding.
After feeding, insulin levels rise, which activates lipogenic
genes through several pathways, including the DNA-
dependent protein kinase (DNA-PK), atypical protein kin-
ase C (aPKC) and AKT-mTOR pathways, as well as protein
phosphatases such as protein phosphatase 1 (PP1) and pro-
tein phosphatase 2 (PP2) [128, 129]. These pathways con-
trol the post-translational modifications of transcription
factors and co-regulators, such as phosphorylation, acetyl-
ation or ubiquitylation that affect their function, stability
and/or localization. In a study BAF60c was identified as
USF-interacting protein and found that BAF60c was phos-
phorylated by aPKC upon feeding/insulin [5]. In response
to insulin/feeding, BAF60c was phosphorylated by aPKC,
causing translocation of BAF60c to the nucleus and allow-
ing a direct interaction of BAF60c with USF-1 that is phos-
phorylated by DNA-PK and acetylated by P/CAF. This
BAF60c phosphorylation, together with USF acetylation is
required for the interaction between two proteins. Further-
more, Overexpression of BAF60c activated the lipogenic
transcription program in mice even in the fasted state.
BAF60c appears to serve as the anchor point bridging USF-
1 and BAF complex for lipogenic gene transcription. Since
BAF60c is the specific isoform for lipogenic gene activation,
defined the USF-1 interacts with BAF60c recruits BAF sub-
units, including BAF155, BAF190, and BAF250 for the for-
mation of the lipoBAF for lipogenic gene transcription,
which is based on phosphorylation dependent translocation
of BAF60c. Therefore, USF acetylation and BAF60c phos-
phorylation are required for the interaction between both
in converging insulin signals [51].
BAF60c induces lipogenesis in feeding/insulin
The liver is the organ responsible for the conversion of
excess carbohydrates to fatty acids to be stored as triglyc-
erides or burned in muscle. A classic action of insulin is to
stimulate fatty acid synthesis in liver during times of
carbohydrate excess. Lipogenesis in liver is under nutri-
tional and hormonal control. Enzymes involved in these
processes are tightly and coordinately regulated during
fasting and feeding/insulin at the transcriptional level. It
should be noted that insulin and glucagon also exert a
posttranslational control of fatty acid synthesis through
changes in the phosphorylation and activation of acetyl-
CoA carboxylase. The transcription of these enzymes is
low in fasting, whereas a high carbohydrate meal that
raises insulin levels activates the lipogenic transcription
program [126, 130, 131]. Insulin-mediated activation of
atypical PKCζ/λ via the PI3K pathway induces SREBP-1c
expression and lipogenesis [132–136].
BAF60c is phosphorylated by aPKC, which causes trans-
location of BAF60c to the nucleus and allows a direct inter-
action of BAF60c with phosphorylated/acetylated USF.
This phosphorylation, together with USF acetylation are re-
quired for the interaction between two proteins. BAF60c
forms the lipoBAF complex for chromatin remodeling that
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is required for activation of the lipogenic program. BAF60c
overexpression activates the lipogenic program by increas-
ing expression of a variety of lipogenic enzymes, including
FAS, ACC, ACL, stearoyl-CoA desaturase-1(SCD1) [18].
Thus, forced overexpression of BAF60c enhanced lipogen-
esis in vivo even in the fasted condition when no significant
de novo lipogenesis is expected to normally occur. Overall,
BAF60c plays important roles in chromatin remodeling and
transcription of lipogenic genes in response to insulin.
Multiple lines of evidence suggest that the stimulatory
effect of insulin on fatty acid synthesis is mediated by an
increase in SREBP-1c. The elevated SREBP-1c increases
lipogenic gene expression, enhances fatty acid synthesis,
and accelerates triglyceride accumulation [137, 138]. The
transcription of SREBP-1c is regulated by three factors
selectively: LXRs, insulin, and glucagon. One study
found that the bHLH domain of USF directly interacts
with the bHLH and an N-terminal region of SREBP-1c
for their synergistic activation of the promoter [6]. The
closely spaced arrangement of the E-box and SRE in
many lipogenic promoters could allow USF and SREBP-
1c to cooperatively activate lipogenic gene transcription
[6]. Co-immunoprecipitation studies using USF-1 mu-
tants containing S262D and S262A showed that S262
phosphorylation increases its interaction with SREBP-1c
[128]. Another study found that SREBP-1c binding to
SRE is USF dependent, as SREBP-1c could not bind SRE
in the FAS promoter when the nearby E-box was mu-
tated [139]. The requirement of USFs for SREBP-1c
function was revealed by USF knockout mice that
showed severely delayed FAS induction during feeding,
even when the level of the mature form of the SREBP
remained unchanged [84]. In addition, SREBP-1, which
itself is induced upon feeding/insulin treatment is in-
volved in the activation of lipogenic genes [79], was also
identified to be activated upon BAF60c overexpression.
Thus, USF bound to the -65 E-box recruits SREBP-1c to
bind the nearby SRE during feeding/insulin Further-
more, functional domain mapping using USF1- and
SREBP1c-deletion constructs indicated that the activa-
tion domains of both proteins are required for this func-
tional synergy. This indicates that post-translational
modifications of USF-1 are crucial for the recruitment of
SREBP-1c to bind to the nearby SRE for the synergistic
activation of lipogenic genes by USFs and SREBP-1c dur-
ing feeding or insulin treatment [128]. Taken together,
identification of SREBP-1c, BAF60c as USF interacting
proteins has led to the discovery of novel players in insu-
lin signaling cascade and has revealed an unexpected
link between DNA break/repair and metabolism.
Conclusion
The liver plays a considerable role in the homeostasis of
lipid metabolism. It regulates several major aspects of
lipid metabolism, including lipogenesis, lipoprotein uptake
and secretion, and fatty acid β-oxidation. Fatty acids serve
as an important source of energy as well as energy storage
for many organisms and are also pivotal for a variety of
biological processes, including the synthesis of cellular
membrane lipids and generation of lipid-containing mes-
sengers involved in signal transduction [140]. Fatty acids
can generally be stored efficiently as non-toxic triglycerids.
Accordingly, the regulation of lipid metabolism is critical
since deregulated lipogenesis and fatty acid oxidation
physiological processes are often linked to pathological
conditions including hepatic steatosis, diabetes, and car-
diovascular disease. Recent studies have been implicated
in hepatic steatosis, occurring when the balance of trigly-
ceride is disrupted, due to increased de novo lipogenesis
and fatty acid uptake and reduced fatty acid oxidation and
very low-density lipoprotein [141, 142], but the molecular
is still poorly understood. Recently, studies proposed that
n-3 PUFA is a qualified nutritional regimen fighting
against metabolic disorders [143]. Thus, the regulation of
lipid metabolism may be targeted to therapeutic hepatic
steatosis.
However, lipid metabolism is mediated by transcription
factors BAF60a and BAF60c, all of which are positive
modulators of hepatic triglyceride contents by targeting
genes coding for key reactions in lipid metabolism. The
recruitment of BAF60a is mediated by PGC-1α to PPARa-
binding sites, leading to transcriptional activation of
hepatic fatty acid oxidation genes, as discussed above.
Phosphorylation and recruitment of BAF60c promotes
lipogenesis and increases triglyceride levels in response to
feeding and insulin. Thus, BAF60a and BAF60c define a
critical link between the SWI/SNF chromatin-remodeling
complexes and hepatic lipid metabolism. Additionally, the
SWI/SNF chromatin-remodeling complexes play import-
ant roles in the regulation of hepatic lipid metabolism.
Interestingly, previous studies demonstrated the expected
heterogeneity in levels between periportal and perivenous
hepatocytes, for example, the activities of various enzymes
and metabolic functions. Remarkably, lipid metabolism is
also zoned in these two hepatic regions. Fatty acid oxida-
tion is exclusively active periportal hepatocytes, whereas
lipogenesis is exclusively active perivenous hepatocytes.
Zonal-specific expression has also been established for
key enzymes of lipid metabolism, showing, for example,
a higher activity of 3-hydroxyacyl-CoA dehydrogenase
in periportal cells compared to perivenous hepatocytes.
In a word, under the control of nutritional and hormo-
nal signals, lipid metabolism is regulated through
BAF60a and BAF60c in periportal and perivenous hepa-
tocytes, respectively (Fig. 2). Therefore, functions and
expression of BAF60a and BAF60c may be associated
with hepatocyte heterogeneity. Whether other subunits
of the SWI/SNF chromatin-remodeling complexes have
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the zonal hepatocyte-characteristic heterogeneity that is
responsible for the regulation of metabolic differences.
There is increasing evidence that alterations in chromatin
remodeling play a significant role in human disease. Alter-
ation of DNA-histone contacts within a nucleosome in an
ATP-dependent manner changes the chromatin structure.
The SWI/SNF complex is an ATP-dependent chromatin-
remodeling complex. Subunits of SWI/SNF complexes have
recently been implicated as tumor suppressors in human
malignancies [144]. It primarily disorganizes and reorga-
nizes nucleosome positioning to promote accessibility for
transcription-factor binding and gene activation, and
regulates both transcriptional activation and repression.
It also plays an important role in regulation of lipid me-
tabolism during different nutritional and hormonal
conditions, as the SWI/SNF complex might be targeted
to develop drugs aimed at regulation of lipid homeosta-
sis in hepatic steatosis. In this review, we present novel
insight into therapeutics of hepatic steatosis through
the SWI/SNF chromatin-remodeling complexes regu-
lates lipid homeostasis.
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feeding/insulin. Phosphorylated BAF60c translocates from the cytosol to the nucleus and directly interacts with phosphorylated/acetylated USF, thus
allowing recruitment of lipoBAF and remodeling of chromatin to activate lipogenic genes. USF-1, which is phosphorylated by DNA-PK and then
acetylated by P/CAF, recruits BAF60c. DNA-PK is activated by PP1. USF-1 bound to the -65 E-box recruits SREBP-1c to bind the nearby SRE during
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